Skip to Content
Merck
  • Exploring the Impact of PARK2 Mutations on the Total and Mitochondrial Proteome of Human Skin Fibroblasts.

Exploring the Impact of PARK2 Mutations on the Total and Mitochondrial Proteome of Human Skin Fibroblasts.

Frontiers in cell and developmental biology (2020-07-01)
Mara Zilocchi, Ilaria Colugnat, Marta Lualdi, Monica Meduri, Federica Marini, Victor Corasolla Carregari, Mohamed Taha Moutaoufik, Sadhna Phanse, Luisa Pieroni, Mohan Babu, Barbara Garavaglia, Mauro Fasano, Tiziana Alberio
ABSTRACT

Mutations in PARK2 gene are the most frequent cause of familial forms of Parkinson's disease (PD). This gene encodes Parkin, an E3 ubiquitin ligase involved in several cellular mechanisms, including mitophagy. Parkin loss-of-function is responsible for the cellular accumulation of damaged mitochondria, which in turn determines an increment of reactive oxygen species (ROS) levels, lower ATP production, and apoptosis activation. Given the importance of mitochondrial dysfunction and mitophagy impairment in PD pathogenesis, the aim of the present study was to investigate both total and mitochondrial proteome alterations in human skin fibroblasts of PARK2-mutated patients. To this end, both total and mitochondria-enriched protein fractions from fibroblasts of five PARK2-mutated patients and five control subjects were analyzed by quantitative shotgun proteomics to identify proteins specifically altered by Parkin mutations (mass spectrometry proteomics data have been submitted to ProteomeXchange with the identifier PXD015880). Both the network-based and gene set enrichment analyses pointed out pathways in which Rab GTPase proteins are involved. To have a more comprehensive view of the mitochondrial alterations due to PARK2 mutations, we investigated the impact of Parkin loss on mitochondrial function and network morphology. We unveiled that the mitochondrial membrane potential was reduced in PARK2-mutated patients, without inducing PINK1 accumulation, even when triggered with the ionophore carbonyl cyanide m-chlorophenylhydrazone (CCCP). Lastly, the analysis of the mitochondrial network morphology did not reveal any significant alterations in PARK2-mutated patients compared to control subjects. Thus, our results suggested that the network morphology was not influenced by the mitochondrial depolarization and by the lack of Parkin, revealing a possible impairment of fission and, more in general, of mitochondrial dynamics. In conclusion, the present work highlighted new molecular factors and pathways altered by PARK2 mutations, which will unravel possible biochemical pathways altered in the sporadic form of PD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Goat Anti-Rabbit IgG Antibody, Peroxidase Conjugated, 1 mg/mL (after reconstitution), Chemicon®
Supelco
N-(Propionyloxy)succinimide, for LC-MS derivatization, LiChropur, ≥95% (HPLC)
Sigma-Aldrich
Anti-RAB7A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Mitochondria Isolation Kit, sufficient for 50 applications (2-5 x 107 cells), isolation of enriched mitochondrial fraction from cells
Sigma-Aldrich
Goat Anti-Mouse IgG Antibody, HRP conjugate, Upstate®, from goat
Sigma-Aldrich
Monoclonal Anti-ATP Synthase β antibody produced in mouse, 1 mg/mL, clone 4.3E8.D10, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-Histone H3 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-CS antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL2548, purified immunoglobulin, buffered aqueous glycerol solution